Biocompatible Synthetic Conduits To Treat Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$421,818.00
Summary
Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular diseas ....Clinically available synthetic conduits used in vascular repair and bypass are fundamentally incompatible with the vasculature. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of all polymeric materials and have shown a significant improvement in their compatibility. Grafts coated using our technology stand to dramatically improve the treatment of vascular disease.Read moreRead less
Preclinical Validation Of First In Man Endovascular Brain Machine Interface Device
Funder
National Health and Medical Research Council
Funding Amount
$870,000.00
Summary
The stentrode technology has been given significant public attention, following publication in the fourth highest impact factor journal 'Nature Biotechnology' and a public statement of endorsement by the President of the United States in 2016. The program now seeks to conduct a preclinical validation program to satisfy the FDA in its requirements to provide Investigational Device Exemption (IDE).
Development Of Endovascular Stents With Proactive Biocompatibility
Funder
National Health and Medical Research Council
Funding Amount
$428,470.00
Summary
Metallic cardiovascular implants, such as stents, used in the treatment of heart disease are not compatible with blood. They cause inflammation at the site of implantation and increase the risk of blood clots forming. We have developed a unique method of binding bioactive protein layers to the surface of metal alloys, and shown a significant improvement in their compatibility. Stents coated using our technology stand to dramatically improve the treatment of cardiovascular disease.
Validating A Prototype Laser System For Intraocular Surgery
Funder
National Health and Medical Research Council
Funding Amount
$495,551.00
Summary
Intraocular surgery is a vital tool for treating common sight threatening diseases such as proliferative diabetic retinopathy and retinal vein occlusion. We seek to develop a prototype laser system to replace currently used mechanical instruments. We have demonstrated that UV laser ablation can afford much greater precision. Laser parameters for the new system will be optimised based on our previous achievements. The new system will be tested in animal trials and clinically.
Novel Therapy For Enhancing Organ Maturation In Pre-term Babies
Funder
National Health and Medical Research Council
Funding Amount
$694,323.00
Summary
This project is developing a factor to enhance organ maturation and repair that may provide a new therapy for premature babies and fetuses with birth defects. This exciting new finding allows for the development of treatments of underdeveloped organs, in particular the lungs of premature and growth restricted babies. We are also trialing this factor in unborn babies with defects to the kidneys and lungs of which there is currently no cure.
Sensitizing Tumours To Immunotherapy: Development Of An RNA-based Therapeutic For Pancreatic Adenocarcinoma That Targets The Immunosuppressive Tumour Microenvironment.
Funder
National Health and Medical Research Council
Funding Amount
$192,347.00
Summary
The blood vessels of tumours are highly abnormal resulting in leakiness and hypoxia within the microenvironment. These abnormalities contribute both to the pathology and also to resistance to treatment. We have developed a new drug that is able to inhibit vascular leak, better the response to therapies and improve disease outcome. This work will generate essential data for the development of this drug towards Clinical Trials through interaction with International Pharma.
Development Of A Safe Live Genetically Attenuated Blood Stage Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$822,191.00
Summary
Malaria presents an enormous global health problem, and also has a significant impact on social and economic development in countries where the disease is endemic. Our project will produce a live genetically-modified vaccine against Plasmodium falciparum, the parasite that causes the form of malaria mostly deadly to humans. Our development plan will include the first ever clinical trials of a malaria vaccine of this kind and will look at vaccine safety and effectiveness.
Optimisation Of A Potent And Fast Acting Antimalarial Class That Is Orally Efficacious In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$683,916.00
Summary
Malaria is a devastating disease that results in 600 000 deaths annually. Current therapeutics used to combat malaria have a limited duration of use in the clinic due to the onset of resistance. We have identified a highly active antimalarial series that we propose to further develop to meet the prerequisites required for partnership with the Medicines for Malaria Venture (MMV) for progression into the clinic.
OctapeptinX Potentiators To Treat XDR Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$1,377,149.00
Summary
There is an urgent need for the development of new antibiotics to treat drug-resistant infections, with the World Health Organisation and other agencies warning of a critical threat to human health. Potentiators are drugs that help obsolete antibiotics regain activity against resistant bacteria. We aim to develop a novel class of potentiators, the octapeptins, to resurrect the activity of old antibiotics so they can be used to treat infections caused by highly-resistant Gram-negative bacteria.
Development Of A Modified Gp130 Ligand To Treat Obesity-induced Insulin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$438,533.00
Summary
IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in tr ....IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in treating insulin resistance and type 2 diabetes.Read moreRead less